Navigation Links
ImpactRx Releases 2010 Oncology Promotion Report
Date:1/31/2011

MOUNT LAUREL, N.J., Jan. 31, 2011 /PRNewswire/ -- ImpactRx, a pioneer in tracking and evaluating pharmaceutical promotion on the prescribing behavior of physicians, completed its annual review of the detailing efforts of pharmaceutical/biotech sales representatives in oncology offices.  The results have just been published in the January 2011 edition of Oncology Business Review.

ImpactRx's mobile pharmaceutical market research system offers a longitudinal network of 475 oncologists who use iPhone technology and proprietary software to provide real-time data about sales representative promotion, meeting and event participation and patient treatment options.  This year the data was supplemented with research into physicians' online behavior provided through a joint offering ImpactRx has with comScore, a global leader in measuring digital traffic and readership.  The result is a unique view of the promotional landscape in the fast-paced and ever-changing oncology market, helping pharmaceutical companies make the most of every minute with key physicians.

According to Richard Altus, President and CEO of ImpactRx, "Given the recent changes in the pharmaceutical and biotech industries, face time with oncologists is more valuable than ever.  This data helps refine brand and targeting strategies to ensure that the right message gets to the right physicians, providing an optimized and powerful marketing strategy."

Click here http://www.impactrx.com/pdf/OBR_93850_IMPACTRX.pdf  to download "The 3rd Annual Outlook on the Pharmaceutical Promotional Landscape within Oncology".

Key data highlighted in the article includes:

  • Share of Attention – Sales Representative Oncology Product Details 2006-2010
  • Top 25 Products Detailed by Sales Representatives 2009/2010
  • Oncology Sales Force Top Tier Rating 2010
  • Reach of Healthcare Website
    '/>"/>

  • SOURCE ImpactRx
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
    2. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
    3. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
    4. CEL-SCI Corporation Releases Letter to Shareholders
    5. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
    6. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
    7. Immunosyn Corporation Releases SF-1019 Study Results
    8. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
    9. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
    10. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
    11. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
    (Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
    (Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
    Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
    ... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported ... announced the selection of its,disinfectant, EnviroTru(TM) for ... (Metro). EnviroTru(TM) is a multi-purpose disinfectant ... also meets EPA requirements for,Toxicity Category IV ...
    ... of statins treated for 3 months with 200 mg/week mipomersen experienced ... continues to support mipomersen,s ... safety profile,- Isis hosting Analyst & Investor Day today - webcast live at 9:00 ... at http://www.isispharm.com , ...
    Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 2Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 4Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 5Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 6Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 7
    (Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
    (Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
    (Date:8/22/2014)... (PRWEB) August 22, 2014 Restore ... Sen and Dr. Samantha Pearson to help people discover ... avoid corrective vision surgery by instead improving their eyesight ... an investigative review. , “There’s a reason why ... in revenue each year—it’s because people just assume that ...
    (Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
    (Date:8/22/2014)... Dayton Children's Hospital broke ground on a historic ... $141 million campus renewal. Renderings of the ... the public. , The new patient tower is part ... campus that meets the needs of patients, families and care ... embody Dayton Children’s unique patient care mission and offer places ...
    Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
    ... be, presented at 59th Annual Meeting of the American Association for the ... ... Oct. 31 ,Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ... 59th Annual Meeting of the American Association for the Study,of Live Diseases ...
    ... CHAPEL HILL, N.C., Oct. 31 Survival nurtures ... rely on their,customers, and employees, innovations in marketing, ... market share., Network with and learn from ... Annual Customer Experience Conference:,Integrated Customer Strategies that Enable ...
    ... a coma, 6 year chronic sciatica back pain, 15- and ... all these conditions were overcome using advanced magnetic therapy techniques ... ... Pennsylvania (PRWEB) October 31, 2008 -- Regenerating nerves, waking people ...
    ... published finds that, while about 40 percent of women ... that those issues are a source of significant personal ... Hospital (MGH) physician appears in the November issue of ... are common in women, but problems associated with personal ...
    ... Normal-weight women who carry out lots of vigorous exercise ... than those who don,t exercise vigorously. A study of ... BioMed Central,s open access journal Breast Cancer Research, ... a risk factor for the disease even in ...
    ... Nanoparticles Present in 4 out of 5,Sunscreens, Even ... N.Y., Oct. 30 Consumers Union,nonprofit publisher of ... 4 out of 5 sunscreens that claimed not ... urged the FDA to,require a full safety assessment, ...
    Cached Medicine News:Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 2Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 3Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 4Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 5Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 6Health News:Survive the Economic Downturn Through Innovations in Integrated Customer Strategies 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 3Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 4Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 5Health News:While prevalent, sexual problems in women not always associated with distress 2Health News:Vigorous activity protects against breast cancer 2Health News:Consumers Union Urges FDA to Conduct Full Scale Safety Review of Nanoparticles in Sunscreen 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: